[go: up one dir, main page]

MX2014002289A - Anticuerpos fc especificos en tandem. - Google Patents

Anticuerpos fc especificos en tandem.

Info

Publication number
MX2014002289A
MX2014002289A MX2014002289A MX2014002289A MX2014002289A MX 2014002289 A MX2014002289 A MX 2014002289A MX 2014002289 A MX2014002289 A MX 2014002289A MX 2014002289 A MX2014002289 A MX 2014002289A MX 2014002289 A MX2014002289 A MX 2014002289A
Authority
MX
Mexico
Prior art keywords
tandem
binding sites
tfc
bispecific antibodies
region
Prior art date
Application number
MX2014002289A
Other languages
English (en)
Inventor
Neeraj Kohli
Briam Harms
Stephen Su
Alexey Lugovskoy
Melissa Geddie
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of MX2014002289A publication Critical patent/MX2014002289A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente proporciona anticuerpos FCs en tándem y Fc en tándem ("TFcAs"), por ejemplo, anticuerpos FC biespecíficos en tándem ("TFc-BAs"), los cuales comprenden uno o al menos dos sitios de unión que específicamente se unen a uno o más receptores de superficie de célula. Los sitios de unión están conectados través de un TFc, dicho TFc comprende una primera región Fc y segunda región Fc, en donde las primera y segunda regiones están enlazadas a través de un enlazador TFc para formar polipéptido contiguo y dimerizan para formar un dímero Fc. TFcBAs ilustrativos inhiben la transducción de señal a través receptor(es) de superficie de célula para el cual los sitios de unión del TFcBA son específicos.
MX2014002289A 2011-08-26 2012-08-27 Anticuerpos fc especificos en tandem. MX2014002289A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161527802P 2011-08-26 2011-08-26
PCT/US2012/052490 WO2013033008A2 (en) 2011-08-26 2012-08-27 Tandem fc bispecific antibodies

Publications (1)

Publication Number Publication Date
MX2014002289A true MX2014002289A (es) 2015-03-20

Family

ID=46759126

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002289A MX2014002289A (es) 2011-08-26 2012-08-27 Anticuerpos fc especificos en tandem.

Country Status (11)

Country Link
US (2) US20140294834A1 (es)
EP (1) EP2748197A2 (es)
JP (1) JP2015527869A (es)
KR (1) KR20140054268A (es)
CN (1) CN103857700A (es)
AU (1) AU2012300279A1 (es)
CA (1) CA2843158A1 (es)
HK (1) HK1199883A1 (es)
IL (1) IL230772A0 (es)
MX (1) MX2014002289A (es)
WO (1) WO2013033008A2 (es)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
JP5953303B2 (ja) 2010-07-29 2016-07-20 ゼンコア インコーポレイテッド 改変された等電点を有する抗体
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
UY35148A (es) * 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US10738132B2 (en) 2013-01-14 2020-08-11 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
CA2897987A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
TW201444872A (zh) 2013-03-06 2014-12-01 Merrimack Pharmaceuticals Inc 抗Ｃ－ＭＥＴ串聯Ｆｃ雙特異性抗體
EP3587448B1 (en) * 2013-03-15 2021-05-19 Xencor, Inc. Heterodimeric proteins
AU2014232416B2 (en) 2013-03-15 2017-09-28 Xencor, Inc. Modulation of T Cells with Bispecific Antibodies and FC Fusions
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
CN104418947A (zh) * 2013-09-11 2015-03-18 香港大学 抗her2和抗-igf-ir的双特异性抗体及其用途
GB201316744D0 (en) * 2013-09-20 2013-11-06 Genovis Ab Method
KR20160083949A (ko) * 2013-11-13 2016-07-12 자임워크스 인코포레이티드 Egfr 및/또는 her2를 표적화하는 1가 항원 결합 작제물 및 이의 용도
TW201609805A (zh) 2013-12-23 2016-03-16 美國禮來大藥廠 結合ｅｇｆｒ及ｍｅｔ之多功能抗體
CN106164094B (zh) * 2014-03-21 2021-05-14 X博迪公司 双特异性抗原结合多肽
MX385936B (es) 2014-03-28 2025-03-11 Xencor Inc Anticuerpos biespecíficos que se unen a cd38 y cd3.
US9975960B2 (en) 2014-05-09 2018-05-22 Samsung Electronics Co., Ltd. Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same
CN105085680A (zh) * 2014-05-23 2015-11-25 复旦大学 人源化抗PD-1及c-MET双特异性抗体及其制备方法和应用
EP3169776B1 (en) * 2014-07-14 2025-09-03 The Regents of The University of California Crispr/cas transcriptional modulation
KR101631646B1 (ko) * 2014-10-16 2016-06-20 주식회사 파멥신 VEGFR-2 및 c-Met에 대하여 결합성을 갖는 이중표적항체
WO2016060297A1 (ko) * 2014-10-16 2016-04-21 주식회사 파멥신 VEGFR-2 및 c-Met에 대하여 결합성을 갖는 이중표적항체
PE20171324A1 (es) 2014-11-26 2017-09-11 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y a antigenos tumorales
IL252467B (en) 2014-11-26 2022-06-01 Xencor Inc Heterodimeric antibodies that bind cd3 and cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
US9767555B2 (en) * 2015-01-05 2017-09-19 Case Western Reserve University Disease characterization from fused pathology and radiology data
MA41375A (fr) 2015-01-22 2017-11-28 Lilly Co Eli Anticorps igg bispécifiques et leurs procédés de préparation
MA41459A (fr) 2015-02-03 2017-12-12 Als Therapy Development Inst Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l
CN107530424A (zh) 2015-02-20 2018-01-02 俄亥俄州国家创新基金会 针对nkg2d和肿瘤相关抗原的二价抗体
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
FI3277321T3 (fi) * 2015-04-01 2024-10-31 Anaptysbio Inc T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita
JP6879932B2 (ja) 2015-04-06 2021-06-02 サイトイミューン セラピューティクス， インコーポレイテッドＣｙｔｏｉｍｍｕｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｌｃ 神経膠芽腫のためのｅｇｆｒ指向ｃａｒ療法
WO2017096221A1 (en) * 2015-12-02 2017-06-08 The Rockefeller University Bispecific anti-hiv broadly neutralizing antibodies
AU2016365742A1 (en) 2015-12-07 2018-06-21 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
RU2767329C2 (ru) * 2016-02-06 2022-03-17 Эпимаб Биотерапьютикс, Инк. Иммуноглобулин с тандемными fab-фрагментами и варианты его применения
CN105884897A (zh) * 2016-04-23 2016-08-24 同济大学苏州研究院 抗c-Met单价抗体慢病毒快速表达及应用
MX2018015592A (es) 2016-06-14 2019-04-24 Xencor Inc Anticuerpos inhibidores de puntos de control biespecificos.
US10316088B2 (en) 2016-06-28 2019-06-11 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
UA128669C2 (uk) 2016-10-14 2024-09-25 Ксенкор, Інк. ГЕТЕРОДИМЕРНИЙ Fc-ЗЛИТИЙ БІЛОК IL15/IL15Ra
JP7261158B2 (ja) * 2016-10-19 2023-04-19 インベンラ， インコーポレイテッド 抗体構築物
CN110062885A (zh) 2016-11-01 2019-07-26 安奈普泰斯生物有限公司 针对t细胞免疫球蛋白和粘蛋白3（tim-3）的抗体
MA47206A (fr) 2017-01-09 2019-11-13 Tesaro Inc Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3
CA3064697A1 (en) * 2017-04-19 2018-10-25 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
AU2018271915B2 (en) 2017-05-24 2025-03-27 Als Therapy Development Institute Therapeutic anti-CD40 ligand antibodies
EP3645122A1 (en) 2017-06-30 2020-05-06 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
JP2021502100A (ja) 2017-11-08 2021-01-28 ゼンコア インコーポレイテッド 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
US11319355B2 (en) 2017-12-19 2022-05-03 Xencor, Inc. Engineered IL-2 Fc fusion proteins
CN111836630A (zh) * 2018-01-05 2020-10-27 希望之城 多特异性配体结合物
CN110028584B (zh) * 2018-01-12 2021-04-06 北京科昕生物科技有限公司 针对egfr蛋白和met蛋白的双特异性抗体
KR20200139189A (ko) * 2018-03-30 2020-12-11 메뤼스 엔.페. 다가 항체
WO2019195623A2 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
KR20210003814A (ko) 2018-04-18 2021-01-12 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
CA3097593A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
CA3108460A1 (en) * 2018-07-04 2020-01-09 Cytoimmune Therapeutics, Inc. Compositions and methods for immunotherapy targeting flt3, pd-1, and/or pd-l1
WO2020014526A2 (en) * 2018-07-11 2020-01-16 Anthony Manning Compositions and methods related to engineered fc-antigen binding domain constructs targeted to cd38
CN113382749A (zh) * 2018-07-11 2021-09-10 动量制药公司 与工程化Fc-抗原结合结构域构建体有关的组合物和方法
MX2021000287A (es) * 2018-07-11 2021-09-08 Momenta Pharmaceuticals Inc Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
EP3861016A2 (en) 2018-10-03 2021-08-11 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
IT201800009282A1 (it) 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
CN114173875B (zh) 2019-03-01 2025-04-15 Xencor股份有限公司 结合enpp3和cd3的异二聚抗体
JP2022525703A (ja) * 2019-03-20 2022-05-18 ジャベリン・オンコロジー・インコーポレイテッド 抗ａｄａｍ１２抗体およびキメラ抗原受容体、ならびにそれを含む組成物および方法
BR112022004789A2 (pt) * 2019-09-27 2022-06-21 Agenus Inc Proteínas heterodiméricas
JP2023519347A (ja) * 2020-03-27 2023-05-10 ビオテスト・アクチエンゲゼルシャフト 少なくとも１つの制御性ｔ細胞活性化エピトープを含むタンパク質
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
EP4172194A1 (en) * 2020-07-31 2023-05-03 CureVac SE Nucleic acid encoded antibody mixtures
KR20230166150A (ko) 2020-08-19 2023-12-06 젠코어 인코포레이티드 항-cd28 조성물
CN114106193B (zh) * 2020-08-31 2025-06-13 苏州康聚生物科技有限公司 一种透明质酸结合蛋白聚体及其在检测透明质酸中的应用
JP7731979B2 (ja) * 2020-09-21 2025-09-01 システィミューン， インク． 特異性が増強した二重特異性抗体（ｓｅｂａ）
WO2022150785A2 (en) * 2021-01-11 2022-07-14 Adimab, Llc Variant ch3 domains engineered for preferential ch3 heterodimerization, multi-specific antibodies comprising the same, and methods of making thereof
JP2024511319A (ja) 2021-03-09 2024-03-13 ゼンコア インコーポレイテッド Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체
CN118339188A (zh) * 2021-09-21 2024-07-12 齐鲁普吉湾生物治疗公司 用于制备融合蛋白和双特异性抗体的异二聚体Fc
WO2024211796A1 (en) 2023-04-07 2024-10-10 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to activin a receptor like type 1 (alk1)
WO2025217523A1 (en) * 2024-04-12 2025-10-16 23Andme, Inc. Variant hinge and molecules comprising same

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5468468A (en) 1989-02-09 1995-11-21 The United States Of America, As Represented By The Secretary Of The Department Of Health & Human Services Method for making a monoclonal antibody, monoclonal antibodies to α PD
DE4205148A1 (de) 1991-05-25 1993-01-21 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen c-kit
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US6696548B2 (en) 1993-12-03 2004-02-24 St. Jude Children's Research Hospital Antibodies for recognition of alk protein tyrosine/kinase receptor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6602684B1 (en) 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
EP2270150B2 (en) 1999-04-09 2019-08-07 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
WO2001007082A1 (en) 1999-07-23 2001-02-01 Glaxo Group Limited Combination of an anti-ep-cam antibody with a chemotherapeutic agent
US8071072B2 (en) 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
US20020119148A1 (en) 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
AU2001294175A1 (en) 2000-10-06 2002-04-22 Kyowa Hakko Kogyo Co. Ltd. Method of purifying antibody
EP3690043A1 (en) 2000-10-06 2020-08-05 Kyowa Kirin Co., Ltd. Antibody composition-producing cell
MX349009B (es) 2001-01-05 2017-07-06 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina.
EP1366067B1 (en) * 2001-03-07 2012-09-26 Merck Patent GmbH Expression technology for proteins containing a hybrid isotype antibody moiety
AU2002307037B2 (en) 2001-04-02 2008-08-07 Biogen Idec Inc. Recombinant antibodies coexpressed with GnTIII
DE60239454D1 (de) 2001-05-03 2011-04-28 Merck Patent Gmbh Rekombinanter, tumorspezifischer antikörper und dessen verwendung
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
WO2002102972A2 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
EP1406931A2 (en) 2001-07-19 2004-04-14 Universität Zürich Modification of human variable domains
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
WO2003063893A2 (en) 2002-01-31 2003-08-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Fgfr agonists
US8287864B2 (en) * 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
ATE510561T1 (de) 2002-03-04 2011-06-15 Imclone Llc Kdr-spezifische menschliche antikörper und ihre verwendung
EP1575509B1 (en) 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
US20080008713A1 (en) 2002-06-28 2008-01-10 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
CA2516236A1 (en) 2003-02-13 2004-08-26 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
ITMI20031127A1 (it) 2003-06-05 2004-12-06 Uni Degli Studi Del Piemont E Orientale Am Anticorpi anti-hgf-r e loro uso
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
PT1680140E (pt) 2003-10-16 2011-05-31 Imclone Llc Inibidores do receptor-1 do factor de crescimento de fibroblastos e m?todos de tratamento destes
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
DK1718677T3 (da) 2003-12-19 2012-07-09 Genentech Inc Monovalente antistoffragmenter egnede som terapeutiske midler
KR20150043558A (ko) 2004-07-22 2015-04-22 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
RU2398777C2 (ru) 2004-08-05 2010-09-10 Дженентек, Инк. ГУМАНИЗИРОВАННЫЕ АНТАГОНИСТЫ, НАПРАВЛЕННЫЕ ПРОТИВ c-met
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
EP1846450B1 (en) 2005-02-04 2012-03-28 MacroGenics West, Inc. Antibodies that bind to epha2 and methods of use thereof
PT1871805T (pt) 2005-02-07 2019-12-02 Roche Glycart Ag Moléculas de ligação a antigénios que se ligam ao rfce, vetores que as codificam e as suas utilizações
AU2006229989B2 (en) 2005-03-25 2012-02-02 Genentech, Inc. Methods and compositions for modulating hyperstabilized c-met
MX2007013924A (es) 2005-05-09 2008-01-28 Glycart Biotechnology Ag Moleculas que unen antigeno que tienen regiones fc modificadas y union alterada a receptores fc.
EP2100618B1 (en) 2005-06-17 2014-02-12 ImClone LLC An anti-PDGFRalpha antibody for use in the treatment of metastatic bone cancer
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
RU2434640C2 (ru) 2006-02-09 2011-11-27 Микромет Аг Лечение метастатического рака молочной железы
BRPI0709598A8 (pt) 2006-03-17 2019-01-08 Biogen Idec Inc composições de polipeptídeos estabilizados
TW200815470A (en) 2006-03-30 2008-04-01 Novartis Ag Compositions and methods of use for antibodies of c-Met
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
PL2013236T3 (pl) 2006-04-28 2015-12-31 Delenex Therapeutics Ag Przeciwciała łączące się z zewnątrzkomórkową domeną receptora kinazy tyrozynowej ALK
EP2094733A1 (en) 2006-11-03 2009-09-02 U3 Pharma GmbH Fgfr4 antibodies
UY30776A1 (es) 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
ES2631727T3 (es) 2007-02-16 2017-09-04 Merrimack Pharmaceuticals, Inc. Anticuerpos contra el ErbB3 y usos de los mismos
ES2368764T3 (es) 2007-03-19 2011-11-22 Universität Stuttgart ANTAGONISTAS SELECTIVOS DE huTNFR1.
UA99608C2 (en) 2007-04-17 2012-09-10 Имклоун Ллк PDGFRb-SPECIFIC INHIBITORS
WO2008131575A2 (en) 2007-04-27 2008-11-06 Esbatech Ag Anti-alk antibodies suitable for treating metastatic cancers or tumors
US20090252729A1 (en) * 2007-05-14 2009-10-08 Farrington Graham K Single-chain Fc (scFc) regions, binding polypeptides comprising same, and methods related thereto
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
NZ585465A (en) 2007-11-12 2012-12-21 Monoclonal antibodies which bind to the extracellular domain of the axl receptor tyrosine kinase
AR069393A1 (es) 2007-11-21 2010-01-20 Imclone Systems Inc Inhibicion del receptor para la proteina estimulante del macrofago (ron) y metodos para el tratamiento del mismo
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
AU2009206724A1 (en) 2008-01-22 2009-07-30 Biogen Idec Ma Inc. RON antibodies and uses thereof
US20100009390A1 (en) 2008-05-09 2010-01-14 The Regents Of The University Of California Mutant antibodies with high affinity for egfr
US8187601B2 (en) 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
WO2010064090A1 (en) 2008-12-02 2010-06-10 Pierre Fabre Medicament Process for the modulation of the antagonistic activity of a monoclonal antibody
CA2757426A1 (en) * 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-2/anti-c-met antibodies
EP2431393B1 (en) 2009-05-15 2018-05-02 Chugai Seiyaku Kabushiki Kaisha Anti-axl antibody
WO2011028952A1 (en) * 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
BR112012025730B1 (pt) 2010-04-09 2020-12-08 Aveo Pharmaceuticals, Inc anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão
SG185487A1 (en) 2010-05-11 2012-12-28 Aveo Pharmaceuticals Inc Anti-fgfr2 antibodies
AR082017A1 (es) 2010-06-18 2012-11-07 Genentech Inc Anticuerpos anti-axl (receptor de tirosina quinasas) y metodos de uso
CA2804399A1 (en) 2010-07-06 2012-01-12 Aveo Pharmaceuticals, Inc. Anti-ron antibodies

Also Published As

Publication number Publication date
US20140294834A1 (en) 2014-10-02
EP2748197A2 (en) 2014-07-02
US20170218028A1 (en) 2017-08-03
CA2843158A1 (en) 2013-03-07
JP2015527869A (ja) 2015-09-24
HK1199883A1 (en) 2015-07-24
AU2012300279A1 (en) 2014-04-03
KR20140054268A (ko) 2014-05-08
WO2013033008A2 (en) 2013-03-07
IL230772A0 (en) 2014-03-31
WO2013033008A3 (en) 2013-04-25
CN103857700A (zh) 2014-06-11
WO2013033008A9 (en) 2013-06-13

Similar Documents

Publication Publication Date Title
MX2014002289A (es) Anticuerpos fc especificos en tandem.
MX2015011712A (es) Anticerpos biespecificos fc en fila anti-c-met.
MX2012003598A (es) Anticuerpos biespecificos agonistas de receptores de muerte.
MX2020003512A (es) Anticuerpos biespecificos anti-hapteno/anti-receptor de barrera hematoencefalica, complejos de los mismos y su uso como transportadores a traves de la barrera hematoencefalica.
CA2929984C (en) A t cell or natural killer (nk) cell which co-expresses two chimeric antigen receptors (cars)
MX2021010441A (es) Receptores antigenicos quimericos y agentes de union dirigidos a dll3.
MX367730B (es) Receptor de antigeno quimerico multi-cadena y usos del mismo.
CL2013001645A1 (es) Secuencia de acido nucleico aislada que codifica un receptor de antigeno quimerico, el cual comprende un dominio de union a antigeno, un dominio transmembrana, una region de señalizacion coestimulatoria y un dominio de señalizacion cd3 zeta; dicho receptor; celula; vector; y su uso para tratar una enfermedad relacionada con la expresion elevada de un antigeno tumoral.
PH12013501096B1 (en) Low affinity blood brain barrier receptor antibodies and uses therefor
MX367787B (es) Receptores de antígenos quimericos ror1 (ntrkr1) específicos para inmunoterapia del cáncer.
PH12015502479B1 (en) Cd19 specific chimeric antigen receptor and uses thereof
WO2014012085A3 (en) Bispecific asymmetric heterodimers comprising anti-cd3 constructs
MX356947B (es) Anticuerpos bioespecíficos específicos para antígenos que activan células t y un antígeno tumoral y métodos de uso.
WO2011123785A3 (en) Frizzled-binding agents and uses thereof
TN2010000213A1 (en) Wise binding antibodies and epitopes
MX370788B (es) Receptores de antígeno quimérico específico de cd33 para inmunoterapia de cáncer.
WO2012145507A3 (en) Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
CR20140585A (es) Proteinas de union a antigeno st2
WO2012103360A3 (en) Wnt compositions and methods of use thereof
MX379660B (es) Anticuerpo anti-receptor de linfocitos t alfa-beta.
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
WO2010037041A3 (en) Frizzled-binding agents and uses thereof
PH12013502378A1 (en) Fc RECEPTOR BINDING PROTEINS
UA113879C2 (xx) ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
WO2013149111A3 (en) Anti-tlr4 antibodies and uses thereof